Spruce Biosciences, Inc.: 5%+ holders

As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Spruce Biosciences, Inc. The largest reported stake is Orin Hirschman's, at 9.1%. 28 filings are on record since August 13, 2025 (Schedule 13G, July 27, 2026).

Rock Springs Capital Management LP also filed stake reports on 1 other company ↓

Sell to companies like Spruce Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: AWM Investment Company, Inc. · Sole voting: 146,988 · Shared voting: 0 · Sole dispositive: 146,988 · Shared dispositive: 0 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-14 · Reporting person: OrbiMed Advisors LLC · Sole voting: 0 · Shared voting: 132,200 · Sole dispositive: 0 · Shared dispositive: 132,200 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-14 · Reporting person: ADAR1 Capital Management, LLC · Sole voting: 0 · Shared voting: 67,717 · Sole dispositive: 0 · Shared dispositive: 67,717 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Citadel Advisors LLC · Sole voting: 0 · Shared voting: 46,960 · Sole dispositive: 0 · Shared dispositive: 46,960 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-04 · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 160,981 · Sole dispositive: 0 · Shared dispositive: 160,981 · SCHEDULE 13G/A, 2026-08-04

Spruce Biosciences, Inc. has 28 Schedule 13D or 13G filings on record since 2025-08-13. 5 holders' latest filing reports 5% or more of common stock, $0.0001 par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Spruce Biosciences, Inc. and the warning signs.

See Spruce Biosciences, Inc.'s free Snapshot Watch Spruce Biosciences, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Spruce Biosciences, Inc. and the records around it.

Spruce Biosciences, Inc. elsewhere on the record

• Leadership changes Jul 2026
• Form D filing Oct 2025
• Who owns it

Companies that share a holder

• Rock Springs Capital Management LP also filed stake reports on 1 other company: TALPHERA, INC. (Sep 2025)
• ExodusPoint Capital Management, LP also filed stake reports on 3 other companies: RE/MAX Holdings, Inc. (Aug 2026), Keros Therapeutics, Inc. (Feb 2026), ALT5 Sigma Corp (Aug 2025)
• The Carlyle Group Inc. also filed stake reports on 7 other companies: SunPower Inc. (Aug 2026), Q32 Bio Inc. (Jul 2026), Medline Inc. (May 2026)

Want the whole picture on Spruce Biosciences, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Spruce Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Spruce Biosciences, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   30 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Spruce Biosciences, Inc. by CUSIP 85209E208 and gives its principal executive office as 611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO, CA 94080 (SCHEDULE 13G, 2026-08-14).

Purpose of Transaction (Item 4)

The Carlyle Group Inc.

Item 4 of the Schedule 13D is hereby amended as follows: Bali Muralidhar, who represented Abingworth Bioventures VII LP on the Issuer's board of directors, resigned as a director in October 2025.Item 4 of the SCHEDULE 13D/A filed 2026-02-18

Timeline

Swipe the table sideways to see every column.

Questions about who owns Spruce Biosciences, Inc.

Who owns Spruce Biosciences, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of Spruce Biosciences, Inc.: Orin Hirschman (9.1%, Schedule 13G, filed 2026-07-27), BlackRock, Inc. (6.8%, Schedule 13G, filed 2026-07-30), Boone Peter David Mr (6.4%, Schedule 13G, filed 2025-11-24), Integrated Core Strategies (US) LLC (5.8%, Schedule 13G/A, filed 2026-08-04) and AWM Investment Company, Inc. (5.1%, Schedule 13G, filed 2026-08-14).

Who are the largest shareholders of Spruce Biosciences, Inc.?

By the share each holder's latest filing reports, the largest holders of Spruce Biosciences, Inc. on this page are Orin Hirschman (9.1%), BlackRock, Inc. (6.8%) and Boone Peter David Mr (6.4%).

When did Orin Hirschman buy into Spruce Biosciences, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Orin Hirschman on this page is the Schedule 13G, filed 2026-07-27, reporting 9.1%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 28 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Spruce Biosciences, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Spruce Biosciences, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Spruce Biosciences, Inc. is mentioned again
• Find former Spruce Biosciences, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes